Epic Bio is a biotechnology company that focuses on leveraging epigenetics to create new therapeutic possibilities. The company works on developing customized therapies using the epigenome, which controls gene expression in mammalian cells.

Epic Bio

Epic Bio is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.

Data we presented this spring at #ASGCT24 showed the promise of our lead candidate, EPI-321, to uniquely address the epigenetic root cause of #FSHD muscular dystrophy. In this interview with CGTLive, our Head of Therapeutics Alexandra Collin de l'Hortet describes the mode of action of EPI-321 and the robust preclinical dataset that supports its potential to have a transformative impact for people with FSHD: https://lnkd.in/e-uufmYv

Epic is looking forward to participating in Canaccord Genuity Group Inc.'s 44th Annual Growth Conference in Boston next month! Reach out if you would like to schedule time to meet with us.

#EpigeneticEditing #biotechnology

This week we will attend the BMO 2024 Genetic Medicines Summit in New York City. Interested in learning more about our leading epigenetic editing platform? Reach out to set up a meeting at amber.salzman@epic-bio.com. BMO Capital Markets

Our platform includes some of the smallest Cas proteins known to work in human cells (half the size of Cas9!) — and today we’re proud to take a major step toward enabling other scientists to use them as well. Together with our founder Lei (Stanley) Qi, we are launching the first dCasMINI Guide Design Tool, to make designing guide RNA for dCasMINI as easy as it is for the first-generation Cas9 or Cas12a. The tool, which is freely accessible at https://lnkd.in/gz4jbvJ8, allows researchers to generate optimal gRNA sequences to activate or suppress more than 99% of human genes with just a single click. It also provides a comprehensive genome-wide assessment of off-target matches.

To learn more about how the dCasMINI Guide Design Tool works, check out our recent updated preprint: https://lnkd.in/gzYz8bey

Our hope is that this tool makes epigenetic modulation studies quicker and easier to perform, and expands access to dCasMINI for researchers across a wide variety of disciplines.

#biotechnology #CRISPR #epigenetics #guidedesign

The future of CRISPR may not look like the CRISPR you’re familiar with, Epic scientific founder Lei (Stanley) Qi and Yitong Ma write in Nature Portfolio. Certain challenges continue to be issues for CRISPR medicines, including safety concerns, delivery challenges, and limited range of diseases that are conducive to gene editing. The next generation of #CRISPR, including #EpigeneticEditing, are paving the way to “addressing the nuanced and complex nature of many diseases, moving beyond the limitations of current CRISPR applications,” they write.

Read the full article here: https://lnkd.in/dHGRZHWY

Great to see Epic featured in Labiotech.eu's top companies to watch in CRISPR’s next wave of therapeutics! Using modified CRISPR machinery, we’re able to dial up or down the expression of genes, without making any cuts to the DNA. And with our hypercompact CasMINI protein, we can fit our medicines within a single AAV vector.

It’s a very exciting time to be writing the next chapter of #CRISPR! Read the article here: https://lnkd.in/eSD2AZF3

At #ASGCT24 we presented some exciting new data on our best-in-class epigenetic activators, showing that we could robustly and durably activate a target gene in vivo. If you missed our presentation, check out this interview with our Head of Technology Daniel Hart PHD, who spoke with CGTLive about the significance of the results and how they expand upon our leading platform for #EpigeneticEditing.

Today is #WorldFSHDDay. Over 1 million individuals globally suffer from FSHD often have facial muscle weakness and have difficulties in simple tasks, including smiling, lifting their arms, or walking. At #EpicBio, we work tirelessly towards finding a cure for #FSHD and bringing back their smiles!

#epigeneticediting #CureFSHD

Epic scientific founder Lei (Stanley) Qi is one of the world’s leading #CRISPR experts. Recently he shared his thoughts on all things gene editing with Stanford University's Stanford Report — from the basics of CRISPR to its next-generation applications in #EpigeneticEditing. 
 
In the article, Dr. Qi explains how the hypercompact CasMINI, which Epic Bio has an exclusive license to, can be paired with epigenetic editing approaches to potentially treat a vast range of diseases that aren’t amenable to today’s gene editing approaches. 
 
Read the story here: https://lnkd.in/e733n2EG 

#biotechnology

Last week we joined the FSHD Society and members of the #FSHD community in Denver for the annual International Research Congress.
 
Our Head of Therapeutics Alexandra Collin de l'Hortet presented highlights of the IND-enabling data package for our lead candidate EPI-321, an epigenetic therapy for the treatment of FSHD, including updated efficacy and safety data.
 
Thank you to all those who attended and continue to support our mission to develop a new therapeutic approach for people living with FSHD.
 
#IRC2024 #CureFSHD

EPIC

COM:EPIC-BIO

Epic Bio

name

homepage url

country

linkedin url

sector

industry

Description

peer of

Metrics